COVID-19 Clinical Trial
Official title:
An Open Label, Control Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities
To evaluate the efficacy of subcutaneous ropeginterferon alfa 2b ( P1101 combined with standard of care (SOC) compared with standard care alone in adult COVID-19 patients with comorbidities.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 31, 2024 |
Est. primary completion date | May 16, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Willingness to provide a written ICF before entering the study; - 2. Male or non-pregnant female patients, = 18 years of age at the time of enrolment (or other age required by local regulations); - 3. Patient with the diagnosis of COVID-19 and with the Ct value <30 in SARS-CoV-2 RT-PCR; - 4. Patients with any comorbidity below at screening: 1. Hematologic cancer; 2. Solid tumor that requires chemotherapy or other systemic therapy; 3. Well controlled autoimmune diseases; or any other medical comorbidities that requires immunosuppressive therapy; - 5. Non-responder to the treatment of any other anti-SARS-CoV-2 drugs, i.e., remdesivir, nirmatrelvir/ritonavir, and/or molnupiravir; or patients who is not suitable to receive the other anti-SARS-CoV-2 drugs by investigator's judgement and has Ct <30 14 days after the symptom onset of COVID-19. Non-responder is defined as a patient who received remdesivir, nirmatrelvir/ritonavir, and/or molnupiravir but still has Ct <30 14 days after the symptom onset of COVID-19. - 6. Agrees to the collection of nasopharyngeal or pharyngeal swabs and blood sample as per protocol. Exclusion Criteria: - 1. Known history or presence of decompensated cirrhosis of the liver (Child-Pugh B or C) before study entry; - 2. Chronic kidney disease with eGFR <15 mL/min/1.73 m2; - 3. Females who are breast-feeding, lactating, pregnant or intending to become pregnant; - 4. Known history of severe allergic or hypersensitivity reactions to the active substance or to any of the excipients of ropeginterferon alfa-2b; - 5. Known history or presence of poorly controlled or clinically significant medical conditions that are not suitable to be enrolled, at the discretion of the investigator, e.g., major psychiatric (including but not limited to those with severe depression, severe bipolar disorder, schizophrenia, suicidal ideation or history of suicidal attempt) or poorly controlled autoimmune diseases; - 6. Clinically significant medical conditions known to interfere with absorption, distribution, metabolism or excretion of the study drugs; - 7. Patients treated by monotherapy of telbivudine or any other combination therapy with telbivudine within 1 month prior to screening; - 8. Use of an investigational medical product within 1 month prior to screening. |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time from randomization to the achievement of Ct value =30 in SARS-CoV-2 quantitative reverse transcriptase polymerase chain reaction (RT-PCR) | To compare the time from randomization to the achievement of Ct value =30 in SARS-CoV-2 quantitative RT-PCR between the Study and Control groups | Up to Day 57 | |
Secondary | The proportion of patients who achieve Ct value =30 in quantitative SARS-CoV-2 RT-PCR at Day 15, Day 29, and Day 43 | The proportion of patients who achieve Ct value =30 in quantitative SARS-CoV-2 RT-PCR at Day 15, 29, and 43, compared between the Study and Control groups | Up to Day 43 | |
Secondary | Change from randomization in the clinical status | The change from randomization in the clinical status of patient on WHO clinical progression scale at Day 15, 29, and 43, compared between the Study and Control groups | Up to Day 43 | |
Secondary | Change of SpO2 | The change of SpO2 from randomization to Day 15, 29, and 43, compared between the Study and Control groups | Up to Day 43 | |
Secondary | The occurrence and the accumulated duration (days) of supple-mental oxygen | To compare the occurrence and the accumulated duration (days) of supplemental oxygen between the Study and Control groups | Up to Day 57 | |
Secondary | The occurrence and the accumulated duration (days) of mechanical ventilation | To compare the occurrence and the accumulated duration (days) of mechanical ventilation between the Study and Control groups | Up to Day 57 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|